Hi ROEROC,
Agreed. But I think we should going through worst scenario analysis.
1. Other parts of LNK (particularly credit management and funds) drag down the whole company - hence losing PEXA.
2. Too much debt, despite the ability to service it for 12 months. When it comes to renewal of loans coming due in 1-3 years, what are the chances of not able to get renewals ? There is no mention of the specific details of loans in their annual reports (a little too opaque).
3. Why isn't the directors buying at this depressed price ?
Well, I don't really know that general investors like us can get those informations. I still trying to find a few good indirect indicators to say the company is going to be fine in next 3 years.
- Forums
- ASX - By Stock
- LNK
- Ann: COVID-19 pandemic,market volatility & withdrawal of guidance
Ann: COVID-19 pandemic,market volatility & withdrawal of guidance, page-17
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add LNK (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online